Headquartered in Warminster, PA Fiscal year ends December NASDAQ: ABUS arbutusbio.com
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, listed on Nasdaq under the ticker ABUS. The company is developing imdusiran (AB-729), an RNAi therapeutic targeting chronic hepatitis B (cHBV), which has achieved functional cure in 10 patients to date and received FDA Fast Track designation. Arbutus is also developing AB-101, an oral PD-L1 inhibitor for cHBV treatment. Beyond its therapeutic pipeline, the company holds significant intellectual property related to lipid nanoparticle (LNP) technology used in mRNA-based vaccines, which it defends through its exclusive licensee Genevant Sciences. Arbutus owns approximately 16% of Genevant's common equity. The company recently settled LNP patent infringement litigation with Moderna for $950 million (with an additional $1.3 billion contingent payment) and has filed international patent enforcement lawsuits against Pfizer and BioNTech across 21 countries. Updated
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly…
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many…
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with chronic hepatitis B virus infection.
Chris Lange Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, listed on Nasdaq under the ticker ABUS.
The Wall Street consensus 12-month price target for ABUS is $5.36.
